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Introduction
The human fallopian tube is a site of active muscular
contraction, clinical activity, and chemokine secretion
and reception [1–3]. In this regard, it may be considered
an active participant in fertilization and early em-
bryogenesis. In 1986, Devroey et al [4] reported the first
pregnancy from a zygote intrafallopian transfer (ZIFT)
procedure. This technique was aimed initially at treating
couples with underlying male-factor infertility, and who
have undergone unsuccessful gamete intrafallopian
transfer (GIFT) procedures, but ZIFT has since been
expanded to treat all infertility etiologies.
It has been suggested that the transfer of a cleavage
stage embryo into the fallopian tube is more physiologic
than replacement into the uterus, and provides the
most appropriate embryo culture conditions [5–7].
There are several additional theoretical advantages to
ZIFT. The transfer of the zygote at the ampullary portion
of the tube would allow further development before
entry into the uterine cavity, and the zygote could then
enter the uterus at a more advanced stage of development
or in greater synchronization with the uterus. The pre-
SUMMARY
Objective: In vitro fertilization and embryo transfer (IVF-ET) have been increasingly used for treating male-factor
infertility. However, zygote intrafallopian transfer (ZIFT) allows early embryo development to occur within the
natural environment of the tubal lumen. The purpose of this study was to analyze whether the mode of embryo
transfer, ZIFT versus intrauterine ET, affected the pregnancy outcome in the IVF cycle after intracytoplasmic sperm
injection (ICSI) for the treatment of male-factor infertility.
Materials and Methods: A total of 140 ICSI procedures (69 ET, 71 ZIFT) were analyzed. A maximum of four
cleaving embryos were transferred into the fallopian tube or uterine cavity 48 and 72 hours after oocyte retrieval,
respectively. Several variables, including mean age, IVF cycle day 2 hormone levels, peak E2 level, number of
oocytes retrieved, number of embryos transferred, endometrial thickness, pulsatility index and resistance index
of the uterine artery, and clinical pregnancy rate, were analyzed.
Results: The clinical pregnancy rate for ET was 25.4%, versus 24.7% for ZIFT. There was no significant difference
between the two groups in the other variables, except for mean age.
Conclusions: The data presented in this report demonstrate that there was no therapeutic improvement associated
with the increased complexity of ZIFT as compared with intrauterine ET after ICSI for the treatment of
male-factor infertility. With the advent of improvements in culture techniques in the IVF laboratory, intrauterine
ET remains the technique of choice. [Taiwanese J Obstet Gynecol 2004;43(1):25–28]
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sence of numerous growth factors and cytokines in the
human tubal fluid may contribute to the development
of the early embryo, and may enhance implantation [2].
In male-factor infertility, information regarding
fertilization is of utmost interest, and ZIFT allows
confirmation of fertilization before transfer, and allows
the exclusion of polypoid embryos.
There are, however, several disadvantages to ZIFT,
such as the need for general anesthesia, laparoscopy,
and a longer postoperative recovery time. The procedure
entails greater medical risk, is expensive for the patient
(due to the laparoscopic procedure), and imposes signi-
ficant logistic difficulties for the center. There is also a
potentially greater risk of ectopic tubal pregnancy [8].
In vitro fertilization and embryo transfer (IVF-ET) is
an important treatment option for many etiologies of
infertility, and has been increasingly used for treating
male-factor infertility. As we have come to better
understand the requirements of early-stage embryos
and devised more physiologic culture media, clinical IVF
success rates have improved. Furthermore, intracyto-
plasmic sperm injection (ICSI) has revolutionized the
treatment of male-factor infertility, making it possible
to achieve fertilization and pregnancy in even the most
severe male-factor infertility cases [9]. Published reports
of success rates indicate clinical pregnancy rates of
approximately 20–40% when ICSI is used in IVF cycles
[10]. The purpose of this study was to analyze whether
the mode of embryo transfer, ZIFT versus intrauterine
ET, affected the pregnancy outcome in the IVF cycle
after ICSI for the treatment of male-factor infertility.
Patients and Methods
Patients
Between January 1999 and May 2002, all couples under-
going transvaginal oocyte retrieval for nontubal-factor
infertility were offered the opportunity to select the use
of ZIFT versus intrauterine ET. Informed consent was
obtained from all the couples, and the study was
approved by the Institutional Review Board of the
National Cheng Kung University Hospital, Taiwan.
A total of 140 couples with male-factor infertility,
and undergoing ICSI procedures, were analyzed.
Inclusion criteria allowed only first-trial couples with
longstanding male-factor infertility. Couples with fe-
male factors of infertility were excluded. Male-factor
infertility was defined as the persistence of abnormal
semen analyses on two or more occasions, combined
with longstanding infertility, and normal infertility
investigation results for the female partner. Semen
analysis was generally conducted 1 to 2 months prior to
the IVF cycle, following World Health Organization
criteria [11], with results considered abnormal if the
count was less than 20 × l06/mL, if the progressive
motility in the sample was below 50%, or if the percentage
of sperm with normal morphology using strict criteria
was less than 4% [12]. Affected males generally had two
or more suboptimal semen parameters.
All female partners had a basic infertility work-up.
The ovulatory status was assessed using a basal body
temperature chart and endocrinologic profile, and the
tubal status by hysterosalpingography (HSG) or chromo-
laparoscopy. If an additional factor was found at this
work-up, the couple was excluded from the study.
Methods
All patients underwent the previously described stan-
dard long protocol, consisting of pretreatment with a
gonadotropin-releasing hormone analog (GnRH-a)
(Lupron; Abbott Laboratories, North Chicago, Illinois,
USA), followed by stimulation with follicle stimulating
hormone (FSH) (Metrodin-HP; Serono SA, Geneva,
Switzerland) and human menopausal gonadotropin
(HMG) (Pergonal; Serono SA) for controlled ovarian
stimulation [13].
All the recruited subjects had been treated with oral
contraceptive pills (1 tab per day for 21 days) in the
previous menstrual cycle. Beginning from day 21 of the
previous cycle, pituitary down-regulation was accom-
plished with 1 mg/day subcutaneous GnRH-a. The dose
was reduced to 0.5 mg/day from day 2 of the IVF cycle
until the day prior to human chorionic gonadotropin
(hCG) administration. From day 3 of the ensuing menses,
three ampoules (amps) of Metrodin-HP were admini-
stered daily for 4 days. This was then shifted to Metrodin-
HP 1 amp + HMG in various doses (2–3 amps) daily.
Blood samples were taken for estradiol analysis on day
2, day 7, and daily from day 9 of the IVF cycle. When
at least one follicle had a diameter of ≥ 18 mm, and
the serum estradiol level was ≥ 200 pg/mL for each
follicle > 14 mm in diameter, hCG (Profasi; Serono SA)
l0,000 IU was administered intramuscularly, and oo-
cytes were recovered 34 hours later under transvaginal
ultrasound guidance.
Oocytes were collected (defined as D0) and trimmed
of excess cumulus cells using 27-G needles, then treated
with 80 IU/mL hyaluronidase (type VIII; Sigma Chemical
Co, St Louis, MO, USA) for 30 to 60 seconds to com-
pletely remove the cumulus cells. ICSI was carried out
using commercially available injection pipettes (Huma-
gon, Charlottesville, VA, USA). Normal fertilization was
defined by the presence of two pronuclei. D2 ZIFT
transfers were carried out by laparoscopy, using a Cook
Humana catheter. The D3 ET transfers were performed
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using a Labtect or Wallace catheter. Patients were
placed on progesterone and hCG booster injections for
luteal-phase support. Clinical pregnancy was defined as
the presence of at least one observed gestational sac.
Data were collected on patient age and IVF cycle day
2 serum levels of estradiol, progesterone, FSH, and
luteinizing hormone (LH); serum levels of estradiol on
hCG day; total medication dosage of gonadotropin;
number of mature oocytes collected; number of embryos
transferred; endometrial thickness; uterine artery blood
flow velocity indices (pulsatility index, PI and resistance
index, RI); and the clinical pregnancy rate for both ZIFT
and intrauterine ET after IVF with ICSI.
Statistics
Data are presented as mean ± standard deviation (SD).
Comparisons between the two groups were performed
using the Mann-Whitney U-test or one-way analysis of
variance as appropriate. A p value less than 0.05 was
considered statistically significant.
Results
One hundred and forty couples were selected for our
study. The husbands all suffered from idiopathic male-
factor infertility (since no obvious cause for their pro-
blem had been identified). The mean age ± SD of the
women in the ET group (n = 69) was 33.6 ± 5.1 years,
and that of the women in the ZIFT group (n = 71) was
31.3 ± 3.9 years (p < 0.05).
The basic IVF cycle day 2 hormone profile, including
FSH, LH, E2, and progesterone, showed no significant
differences between the two groups (Table). After
controlled ovarian hyperstimulation, there was a ten-
dency toward fewer oocytes retrieved and a slightly
higher gonadotropin dosage in the ET group (p > 0.05).
There were no significant differences in the number of
embryo replacements, endometrial thickness, or uterine
artery blood flow velocity indices (PI and RI) between
the ET and ZIFT groups (Table). The clinical pregnancy
rate for ET was 25.4%, versus 24.7% for ZIFT; the dif-
ference was not significant.
Discussion
The pregnancy rates after the two transfer procedures
revealed no significant differences. Various factors related
to the procedures themselves or related to the indicat-
ion, i.e. male-factor infertility, may explain this finding.
In ZIFT, the normal tubal environment could have been
altered at the time of transfer, e.g. by tissue trauma af-
ter the replacement, by exposure to the blood in the
peritoneal cavity from the ovum pick-up, by the light or
pneumoperitoneum used for laparoscopy, or even by
anesthesia. Another point is the status of the oviduct
itself. Occult intraluminal adhesions and fibrosis or
deciliation of the tubal mucosa are not fully assessed
by HSG or laparoscopy. Tubal patency does not imply
tubal functionality [14]. In most retrospective studies,
increased pregnancy and implantation rates result from
Table. Comparison of variables between the ET and ZIFT groups
ET (n = 69) ZIFT (n = 71) p
Age (yr) 33.6 ± 5.1 31.3 ± 3.9 < 0.05
D2 FSH (mIU/mL) 3.64 ± 3.13 3.08 ± 1.58 NS
D2 LH (mIU/mL) 2.61 ± 5.50 2.49 ± 1.99 NS
D2 E2 (pg/mL) 38.78 ± 19.62 38.46 ± 27.16 NS
D2 Progesterone (ng/mL) 0.65 ± 0.33 0.63 ± 0.29 NS
COH
   Ovulation induction (d) 10.1 ± 1.3 10.0 ± 1.5 NS
   Gonadotropin dosage (amps) 28.3 ± 5.9 26.8 ± 5.8 NS
   E2 on hCG day (pg/mL) 2229.29 ± 1305.26 2524.85 ± 1372.73 NS
   Oocytes retrieved (n) 12.1 ± 9.1 14.8 ± 9.7 NS
   Embryo replacements (n) 3.6 ± 1.2 3.2 ± 1.2 NS
   Endometrial thickness (mm) 11.24 ± 2.71 11.16 ± 2.57 NS
   PI (uterine artery) 2.20 ± 0.54 2.28 ± 0.42 NS
   RI (uterine artery) 0.82 ± 0.08 0.83 ± 0.05 NS
   Pregnancy rate (%) 25.4 24.7 NS
ET = embryo transfer; ZIFT = zygote intrafallopian transfer; FSH = follicle stimulating hormone; NS = not significant; LH = luteinizing hormone;
COH = controlled ovarian hyperstimulation; hCG = human chorionic gonadotropin; PI = pulsatility index; RI = resistance index.
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tubal embryo transfers rather than intrauterine transfers
[5–7]; this is supported by some subsequent non-
randomized prospective studies [15,16]. In contrast,
other studies have shown comparable pregnancy rates
after both transfer techniques [17,18]. The important
variables for success in artificial reproduction techniques
are the patient’s age, underlying cause of infertility,
selecting viable embryos for transfer, and the number of
embryos transferred. Differences in outcome may result
from differences in patient selection.
In this study, only couples with male-factor infertility
were selected, and IVF was restricted to the ICSI pro-
cedure, so we could compare the different modes of
transfer after the confirmation of cleaving embryos. Our
results, in contrast to those of other retrospective stu-
dies [5–7], do not show any therapeutic advantage to
ZIFT over intrauterine ET in this category of couples.
Furthermore, the ZIFT procedure requires laparoscopy
as well as general anesthesia, is longer in duration, and
involves inevitable hospitalization. Its cost is therefore
higher than that of IVF-ET.
Several studies have also revealed no therapeutic
advantage to ZIFT over IVF-ET in male-factor or
nontubal-factor infertility, in terms of reproductive
outcome or economic benefit [14,19,20], but no other
retrospective study compares ZIFT and intrauterine ET
for only couples with male-factor infertility undergoing
ICSI procedures. Currently, we cannot demonstrate a
significant advantage to the use of this more expensive,
inconvenient, and invasive technique. With the advent
of improvements in culture techniques in the IVF
laboratory, intrauterine ET remains the technique of
choice. For ZIFT to become a viable treatment option,
subpopulations in which its use may be of benefit will
need to be identified.
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